|
Malignant neoplasm of prostate
|
0.390 |
Biomarker
|
disease |
BEFREE |
Only AZGP1 was associated with PCa death.
|
30288742 |
2019 |
|
Malignant neoplasm of prostate
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
We aimed to examine the association between AZGP1 expression and the endpoints: risk of biochemical failure (BF), initiating castration-based treatment, developing castration-resistant PCa (CRPC) and PCa-specific mortality following radical prostatectomy (RP).
|
31331953 |
2019 |
|
Malignant neoplasm of prostate
|
0.390 |
Biomarker
|
disease |
BEFREE |
In vivo xenotransplantation tumor experiments also show that AZGP1 involves in androgen/AR axis-mediated PCa cell proliferation.
|
30820960 |
2019 |
|
Malignant neoplasm of prostate
|
0.390 |
Biomarker
|
disease |
BEFREE |
This study prospectively enrolled an independent phase III cohort to evaluate the clinical utility of zinc-alpha 2-glycoprotein (AZGP1) as a prognostic biomarker in localized PC.
|
28486686 |
2017 |
|
Malignant neoplasm of prostate
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
AZGP1 expression was strong in benign prostatic glands but absent in 38.0% of 8,510 interpretable prostate cancers.
|
26383228 |
2016 |
|
Malignant neoplasm of prostate
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
Quantitative RT-PCR analysis revealed that MSMB, NBL1 and AZGP1 were expressed with much higher specificity in PCa and NP than in 14 other kinds of normal tissue.
|
22948749 |
2013 |
|
Malignant neoplasm of prostate
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
These results indicate that upregulation of GATA-2 may contribute to the progression to aggressive prostate cancer through modulation of expression of AR and key androgen-regulated genes, one of which, AZGP1, is associated with the progression to metastatic disease.
|
19684615 |
2009 |
|
Malignant neoplasm of prostate
|
0.390 |
Biomarker
|
disease |
CTD_human |
Integrative molecular concept modeling of prostate cancer progression.
|
17173048 |
2007 |
|
Malignant neoplasm of prostate
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
Low (i.e., absent or weak) AZGP1 expression was associated with clinical recurrence (defined as confirmed localized recurrence, metastasis, or death from prostate cancer; hazard ratio [HR] = 4.8, 95% confidence interval [CI] = 2.2 to 10.7, P<.001) and with bony metastases or death from prostate cancer (HR = 8.0, 95% CI = 2.6 to 24.3, P<.001).
|
17018789 |
2006 |
|
Malignant neoplasm of prostate
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
This study characterized ZAG protein expression in PCa using a semi-automated system.
|
16598739 |
2006 |
|
Polycystic Ovary Syndrome
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, the normoandrogenic type specifically exhibited the highest circulating ZAG levels among all PCOS phenotypes (p < 0.05 or p < 0.01).
|
31748429 |
2020 |
|
Polycystic Ovary Syndrome
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
PCOS women with IR (M-value<6.28) had lower circulating ZAG concentrations, and higher circulating Irisin and Betatrophin levels relative to PCOS women without IR (M-value ≥ 6.28).
|
31683329 |
2019 |
|
Polycystic Ovary Syndrome
|
0.330 |
Biomarker
|
disease |
BEFREE |
Circulating ZAG is closely related to PCOS and could be an important adipokine involved in the occurrence and development of PCOS.
|
30918134 |
2019 |
|
Polycystic Ovary Syndrome
|
0.330 |
Biomarker
|
disease |
CTD_human |
Progesterone resistance in PCOS endometrium: a microarray analysis in clomiphene citrate-treated and artificial menstrual cycles.
|
21411543 |
2011 |
|
Adenocarcinoma
|
0.320 |
AlteredExpression
|
group |
LHGDN |
AZGP1 autoantibody predicts survival and histone deacetylase inhibitors increase expression in lung adenocarcinoma.
|
18978557 |
2008 |
|
Adenocarcinoma
|
0.320 |
AlteredExpression
|
group |
LHGDN |
AZGP1 mRNA levels in normal human lung tissue correlate with lung cancer disease status.
|
17724461 |
2008 |
|
Adenocarcinoma
|
0.320 |
Biomarker
|
group |
CTD_human |
AZGP1 autoantibody predicts survival and histone deacetylase inhibitors increase expression in lung adenocarcinoma.
|
18978557 |
2008 |
|
Malignant neoplasm of lung
|
0.310 |
Biomarker
|
disease |
CTD_human |
AZGP1 autoantibody predicts survival and histone deacetylase inhibitors increase expression in lung adenocarcinoma.
|
18978557 |
2008 |
|
Malignant neoplasm of lung
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
AZGP1 mRNA levels in normal human lung tissue correlate with lung cancer disease status.
|
17724461 |
2008 |
|
Prostatic Neoplasms
|
0.310 |
Biomarker
|
group |
CTD_human |
Integrative molecular concept modeling of prostate cancer progression.
|
17173048 |
2007 |
|
Prostatic Neoplasms
|
0.310 |
AlteredExpression
|
group |
LHGDN |
Characterization of ZAG protein expression in prostate cancer using a semi-automated microscope system.
|
16598739 |
2006 |
|
Sclerocystic Ovaries
|
0.300 |
Biomarker
|
disease |
CTD_human |
Progesterone resistance in PCOS endometrium: a microarray analysis in clomiphene citrate-treated and artificial menstrual cycles.
|
21411543 |
2011 |
|
Lung Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
AZGP1 autoantibody predicts survival and histone deacetylase inhibitors increase expression in lung adenocarcinoma.
|
18978557 |
2008 |
|
Sinusitis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene expression profiling of nasal polyps associated with chronic sinusitis and aspirin-sensitive asthma.
|
18391768 |
2008 |
|
Adenocarcinoma, Basal Cell
|
0.300 |
Biomarker
|
disease |
CTD_human |
AZGP1 autoantibody predicts survival and histone deacetylase inhibitors increase expression in lung adenocarcinoma.
|
18978557 |
2008 |